Clinical Comparisons in CTEPH

Slides:

Advertisements

Similar presentations

Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and post- pulmonary endarterectomy pulmonary hypertension A pre-defined subgroup.

Advertisements

Riociguat directly stimulates the native sGC independently of NO Riociguat increases the sensitivity of native soluble guanylate cyclase (sGC) to NO Both.

PULMONARY ARTERY DENERVATION FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION: RESULTS FROM A CONTROLLED BEFORE AND AFTER STUDY—PADN 2 STUDY Shao-Liang.

Upfront Combination Therapy vs Step-Up Approach for PAH:

Endocrine Combinations in HR-Positive MBC: The Future Is Now

A Framework for Diagnosing and Treating CTEPH

Monitoring and Modifying Treatment in PAH

Update on the Diagnosis and Management of CTEPH in Latin America

Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

A Paradigm Shift in PAH.

An Update on Oral Prostanoids: Advancing Care for PAH?

Identifying and Managing Dyspnea Associated With CTEPH

A CASE CHALLENGE IN HFrEF:

UNDERSTANDING RISK STRATIFICATION IN PAH:

PAD Patients vs Post-ACS Patients:

The Latest Data on Oral Prostacyclin Therapy in PAH

New Treatments for CTEPH

All About PAH:.

Selecting NOACs for High-Risk Patients

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

PAH Therapy Revisited.

PAH in Adults CHEST Guideline and Expert Panel Report: Grading of Evidence

Improving Risk Assessment and Early Diagnosis in PAH

Updates in Pulmonary Arterial Hypertension

WHO Clinical Classification of PH Complex Cases in PH.

Selected Highlights of the Latest Advances in PAH

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Evolving Science of PAH Treatment

PCSK9 Inhibitors and Cardiovascular Outcomes

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

A Better Solution For Cancer Patients With VTE?

2013 World Symposium on PH CTEPH Diagnosisa 2013 World Symposium on PH (cont) CTEPH Treatmenta.

Examining the Latest Evidence in PAH

Has the 6-Min Walk Distance Run Its Course?

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Current and Emerging Data in CTEPH

Case Study 56-year-old Presents With 1 Year of Worsening Dyspnea

The Evolving Treatment Landscape in Atopic Dermatitis

PAH and Prostacyclin Pathways in Focus

Identifying Strategies for Improving Outcomes in Patients With CTEPH

Pulmonary Arterial Hypertension and Connective Tissue Disease

What's New in PAH?.

PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH

Oral Prostacyclin Pathway Agents in PAH

Pulmonary Hypertension Updates From 2018

Elevated Admission Plasma Glucose Following ACS

Reducing Risk for CV Outcomes

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Treatment algorithm for managing chronic thromboembolic pulmonary hypertension (CTEPH), from the European Society of Cardiology/European Respiratory Society.

Live on PAH: Breathing Life Into Patients With PAH

CTEPH in Clinical Practice

Patient Stories in PAH: Sequential Therapy in a FC II Patient

Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Prostacyclin Pathway Agents in Action

Transitioning Therapy in PAH: Practical Strategies and Considerations

Incorporating New PAH Treatments Into Clinical Practice

PAH Pathways: What Do the Data Tell Us?”

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Mean change from baseline in 6MWD in (A) Chinese patients with PAH in PATENT-1 and (B) Chinese patients with CTEPH in CHEST-1. Mean change from baseline.

Pulmonary Arterial Hypertension and Hospitalizations

Merging the Art and Science of Managing nOH in Clinical Practice

What's New in PAH?.

Definition of pulmonary hypertension (PH) associated with left heart disease. mPAP: mean pulmonary arterial pressure; PAWP: pulmonary artery wedge pressure;

Cardiac index (CI) changes from baseline following single oral doses of riociguat (○) 1 mg and 2.5 mg compared with inhaled nitric oxide (•) in patients.

My PAH Patient.

Diagnostic algorithm for chronic thromboembolic pulmonary hypertension

Treatment algorithm for chronic thromboembolic pulmonary hypertension.

The Power of As-Treated Analyses

Presentation transcript:

Clinical Comparisons in CTEPH

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Background

CTEPH Definitions From the International Prospective CTEPH Registry

Medical Therapy Riociguat Mechanism of Action

CHEST-1 Study Design

CHEST-1 Riociguat for the Treatment of CTEPH

CHEST-1 Subgroup Analysis Inoperable and Postoperative Patients

CHEST-1 Safety Results

MERIT-1 Study Design

MERIT-1 Primary Endpoint Results

MERIT-1 Primary Endpoint by Subgroup

MERIT-1 Secondary Endpoint 6MWD

MERIT-1 Safety

Clinical Trials in CTEPH

Clinical Trials in CTEPH Hemodynamic Results

Clinical Trials in CTEPH Functional Capacity Results

CTEPH Is Not Just a Clot Problem

Microvasculopathy Associated With Proximal Disease in CTEPH

Small Vessel Disease May Be a Major Contributor to Persistent/Residual PH

Targeted Pharmacological Therapies for PAH and Possibly CTEPH

CTEPH Treatment Algorithm

Sequential Treatment With Riociguat and BPA in Patients With Inoperable CTEPH

Treatment Response to Multimodality Approach

CTEPH Trials in Progress

CTEPH Management

Conclusion

Abbreviations

Abbreviations (cont)